30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

Company Revenue 2015: Tornier

2Q15:

$83.2MM, +4.0% (U.S. $50.1MM, +2.6%; ex-U.S. $33.1MM, +5.7%)

  • Total Extremities $71.7MM, +6.0%
  • Upper $56.5MM, +11.9%
  • Lower $11.9MM, -13.8%
  • Sports Med/Biologics $3.2MM, -3.0%
  • Large Joints/Other $11.4MM, -5.7%

 

  • Another quarter of above-market growth for Aequalis Ascend™ Flex shoulder
  • Lower extremity growth impacted by expected merger distractions
  • Tornier/Wright merger slated to close in 3Q15

 

1Q15:

$88.1MM, +6% (U.S. $52.9MM, +6%; ex-U.S. $35.1MM, +7%)

Total Extremities $74.8MM, +9%

  • Upper $57.4MM, +14%
  • Lower $13.9MM, -5%
  • Sports Med/Biologics $3.4MM, -4%

Large Joints/Other $13.3MM, -6%

 

  • Upper Extremities led by Aequalis Ascend shoulder products, while Lower reflects growth from total ankle arthroplasty offset by low sales of core foot fixation and distraction from merger activity
  • Received FDA clearance for Simpliciti® shoulder, 1st-to market in U.S. with an ultra-short stem bone sparing system
  • Will commence U.S. launch in later 2Q, ramp up during 2H15, for anticipated impact in 2016
  • Received FDA 510(k) clearance for BLUEPRINT technology, 3D pre-op planning tool with patient-specific placement guides to plan and trial different products
  • On track to launch Ascend Flex platform in Japan by early 2016
  • Company leadership places Tornier in upper teens to 20% range of share in upper extremity market, taking share from DePuy and Biomet
  • Sports Med/Biologics reflects decline in soft tissue anchor/biologics sales
  • Large Joint reflects anticipated deceleration in EU and challenging comp period